Is there any Relationship Between Eosinophilia Myalgia Syndrome (Ems) and Fibromyalgia Syndrome (Fms)? an Analysis Of Clinical and Immunological Data

  • Heidi Barth
  • Peter A. Berg
  • Reinhild Klein
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 467)

Abstract

The eosinophilia-myalgia syndrome (EMS) caused by intake of contaminated L-tryptophan resembles in its clinical presentation the fibromyalgia syndrome (FMS). We, therefore, analysed clinical and immunological parameters in 16 patients with chronic EMS and 100 patients with FMS in order to see whether there may be a relationship between both disorders. From 12 FMS patients and 12 controls also peripheral blood mononuclear cells (PBMC) were obtained. Myalgia and arthralgia was observed in chronic EMS in the same incidence as in patients with FMS (81%). Also antibodies to serotonin, gangliosides and phospholipids were present in both groups. In vitro stimulation of PBMC with different L-tryptophan preparations revealed in six of the 12 FMS patients but only two of the control individuals a production of type 2 cytokines (IL-5, IL-10). We, therefore, conclude that EMS may have developed in patients suffering primarily from FMS as an allergic reaction towards a more immunogenic L-tryptophan preparation.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. AlberatiGiani D. and Cesura A.M., 1998, Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators, Amino Acids 14:251–255.CrossRefGoogle Scholar
  2. Belongia E.A., Hedberg C.W., Gleich G.J., White K.E., Mayeno A.M., Loegering D.A., Dunnette S.L., Pirie PL., MacDonald K.L., and Osterholm MT., 1990, An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N. Engl. J. Med. 323:357–365.PubMedCrossRefGoogle Scholar
  3. Berg P.A. and Becker E.W., 1995, The lymphocyte transformation test-a debated method for the evaluation of drug allergic hepatic injury, Journal of Hepatology 22:115–118.PubMedCrossRefGoogle Scholar
  4. Byrne G.I., Lehmann L.K., Kirschbaum J.G., Borden E.C., Lee C.M., and Brown R.R., 1986, Induction of tryptophan degradation in vitro and in vivo: a gamma interferon-stimulated activity. J. Interferon Res. 6:389–396.PubMedCrossRefGoogle Scholar
  5. Clutterbuck E.J., Hirst E.M., and Sanderson C.J., 1989, Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6 and GM-CSF. Blood 73:1504–1512.PubMedGoogle Scholar
  6. Henning K.J., Jean-Baptiste E., Singh T., Hill R.H., and Friedmann S.M., 1993, Eosinophilia-myalgia syndrome: in patients ingesting a single source of L-tryptophan, J. Rheumatol. 20:273–278.PubMedGoogle Scholar
  7. Hertzman P.A., Falk H., Kilbourne E.M., Page S., and Shulman L.E., 1991, The eosinophilia-myalgia syndrome. The Los Angeles Alamos Conference, J. Rheumatol. 18:867–873.PubMedGoogle Scholar
  8. Hertzmann P.A., Blevins W.L., Mayer J., Greenfield B., Ting M., and Gleich G.J., 1990, Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan, N. Engl. J. Med. 322:869–873.CrossRefGoogle Scholar
  9. Heyes M.P., Achim C.L., Wiley C.A., Major E.O., Saito K., and Markey S.P., 1996, Human microglia convert L-tryptophan into the neurotoxin quinolinic acid, Biochemical Journal 320:595–597.PubMedGoogle Scholar
  10. Kerr S.J., Armati P.J., and Brew B.J., 1995, Neurocytotoxity of quinolinic acid in human brain cultures, Journal of Neurovirology 1:376–380.CrossRefGoogle Scholar
  11. Kerr S.J., Armati P.J., Guillemin G.J., and Brew B.J., 1998, Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex, AIDS 12:355–363.PubMedCrossRefGoogle Scholar
  12. Klein R. and Berg P.A., 1995, High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: Evidence for a clinical entity of both disorders, European Journal of Medical Research 1:21–26.PubMedGoogle Scholar
  13. Klein R., Bänsch M., and Berg P.A., 1992, Clinical relevance of antibodies against serotonin and gangliosides in patients with fibromyalgia syndrome, Psychoneuroendocrinology 17:593–598.PubMedCrossRefGoogle Scholar
  14. Klein R. and Berg P.A., 1994, A comparative study on antibodies to nucleoli and 5—hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinopilia-myalgia syndrome. Clin. Investig. 72:541–549.PubMedCrossRefGoogle Scholar
  15. Lopez A.F., Sanderson C.J., Gamble J.R., Campbell H.D., Young I.G., and Vadas M.A., 1988, Recombinant human interleukin 5 is a selective activator of human eosinophil function, J. Exp. Med. 167:219–224.PubMedCrossRefGoogle Scholar
  16. Mackowiak P.A. and LeMaistre C.F., 1987, Drug fever: a critical appraisal of convential concepts, Ann. Intern. Med. 106:728–733.PubMedCrossRefGoogle Scholar
  17. Manu P., Matthews D.A., and Lane T.J., 1993, Food intolerance in patients with chronic fatigue, International Journal of Eating Disorders 13:203–209.PubMedCrossRefGoogle Scholar
  18. Mayeno A.N., Lin F., Foote C.S., Loegering D.A., Ames M.M., Hedberg C.W., and Gleich G., 1990, Characterization of “peak E”, a novel amino acid associated with eosinophilia-myalgia syndrome, Science 250:1707–1708.PubMedCrossRefGoogle Scholar
  19. Mosmann T.R., Schumacher J.H., Fiorentino D.F., Leverah J, Moore K.W., and Bond M.W, 1990, Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid solid phase radioimmunoadsorbent assay. J. Immunol. 145:2938–2945.PubMedGoogle Scholar
  20. Ozaki Y., Edelstein M.P., and Duch D.S., 1987, The actions of interferon and antiinflammatory agents on induction of indoleamine-2,3-dioxygenase in human peripheral blood monocytes, Biochem. Biophys. Res. Commun. 144:1147–1153.PubMedCrossRefGoogle Scholar
  21. Schwarcz R., Whetsell W.O., and Mangano R., 1983, Quinolinic acid: an endogenous metabolite that produces axonsparing lesions in rat brain, Science 219:316–318.PubMedCrossRefGoogle Scholar
  22. Shulman L.E., 1990, The eosinophilia-myalgia syndrome associated with the ingestion of L-tryptophan, Arthritis Rheum. 33:913–917.PubMedCrossRefGoogle Scholar
  23. Silver R.M., Heyes M.P., Maize J.C., Quearry B., Vionnet-Fussaet M., and Sternberg E.M., 1990, Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan, N. Engl. J. Med. 322:874–881.PubMedCrossRefGoogle Scholar
  24. Silver R.M., McKinley K., Smith E.A., Quearry B., Harati Y., Sternberg E.M., and Heyes M.P, 1992a, Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome, Arthritis and Rheum; 35:1097–1105.CrossRefGoogle Scholar
  25. Silver R.M., Sutherland S.E., Carreira P., and Heyes M.P, 1992b, Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome, J. Rheumatol. 19:69–73.PubMedGoogle Scholar
  26. Slutsker L., Hoesly F.C., Miller L., Williams L.P., Watson J.C., and Fleming D.W., 1990, Eosinophilia-myalgia syndrome associated with the exposure to tryptophan from a single manufacturer, JAMA 264:213–217.PubMedCrossRefGoogle Scholar
  27. Straus S.E., Dale J.K., Wright R., and Metcalfe D.D., 1988, Allergy and the chronic fatigue syndrome, J. Allergy Clin. Immunol. 81:791–795.PubMedCrossRefGoogle Scholar
  28. Varga J., Uitto J., and Jimenez S.A., 1992, The cause and pathogenesis of the eosinophilia-myalgia syndrome, Ann. Intern. Med. 116:140–147.PubMedCrossRefGoogle Scholar
  29. Wolfe F., Anderson J., Harkness D., Bennett R.M., Caro X.J., Goldenberg D.L., Russell I.J., and Yunus M.B., 1997, Health status and disease severity in fibromyalgia: Results of a six-center longitudinal study, Arthritis and Rheum. 40:1571–1579.CrossRefGoogle Scholar
  30. Wolfe F., Hawley D.J., Cathey M.A., Caro X., and Rusell I.J., 1985, Fibrositis: symptom frequency and criteria for diagnosis, J. Rheumatol. 12:1159–1163.PubMedGoogle Scholar
  31. Yamaguchi Y., Hayashi Y., Sugama Y., Miura Y., Kasahara T., Kitamura S., Torisu M., Mita S., Tominaga A., and Takatsu K., 1988, Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. Il-5 as an eosinophil chemotactic factor, J. Exp. Med. 167:1737–1742.PubMedCrossRefGoogle Scholar
  32. Yamaguchi Y., Suda T., Shiozaki H., Miura Y., Hitoshi Y., Tominaga A., Takatsu K., and Kasahara T., 1990, Role of IL-5 in IL-2-induced eosinophilia: In vivo and in vitro expression of IL-5 mRNA by IL-2. The Journal of Immunology 145:873–877.PubMedGoogle Scholar
  33. Yunus M., Masi A.T., Calabro J.J., Miller K.A., and Feigenbaum S.L., 1981, Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls, Semin. Arthritis Rheum. 11:151–171.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Heidi Barth
    • 1
  • Peter A. Berg
    • 1
  • Reinhild Klein
    • 1
  1. 1.Department of Internal MedicineUniversity of TübingenTübingenGermany

Personalised recommendations